|Bid||0.00 x 4000|
|Ask||0.00 x 1200|
|Day's range||7.54 - 7.92|
|52-week range||6.20 - 43.40|
|Beta (5Y monthly)||1.07|
|PE ratio (TTM)||N/A|
|Earnings date||02 Aug 2022 - 08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||17.25|
Because of this stock market crash, some wonderful stocks are super cheap in 2022. Here's a mini-portfolio of innovative companies trading under $10 a share right now.
Ladies and gentlemen, thank you for standing by, and welcome to the Adaptive Biotechnologies first quarter 2022 financial results conference call. In addition, Harlan Robins, Adaptive chief scientific officer and co-founder; Nitin Sood, head of our MRG business; and Sharon Benzeno, head of the immune medicine business, will be available for Q&A. With that, I'll turn the call to Chad Robins.
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of -2.33% and 0.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?